DGAP-News: Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference
DGAP-News: Sernova Corp.
/ Key word(s): Study results/Study
LONDON, ONTARIO - January 5, 2022 - Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine and cell therapy therapeutics company focused on developing a potential 'functional cure' for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce that new interim results from the ongoing safety, tolerability and efficacy Phase I/II clinical trial of Sernova's Cell Pouch(TM) will be released on January 10, 2022. Originally, it was planned that Dr. Piotr Witkowski, principal investigator of Sernova's Phase I/II clinical trial would present an update in a poster session at the American Society of Transplant Surgeons (ASTS) 22nd Annual "State of the Art" Winter Symposium on January 13, 2022, but the conference was postponed yesterday until the end of July 2022 because of the ongoing COVID-19 pandemic. "We are pleased to be announcing these new interim data earlier than anticipated in conjunction with the J.P. Morgan conference which is one of the premier international healthcare conferences," said Dr. Philip Toleikis, President & CEO of Sernova. ABOUT THE J.P. MORGAN HEALTHCARE CONFERENCE The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry which connects global industry leaders, emerging fast growth companies, innovative technology creators and members of the investment community. The J.P. Morgan 40th Annual Healthcare Conference (JPM 2022) will take place virtually, January 10-13, 2022. ABOUT SERNOVA The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase I/II study at the University of Chicago. Positive initial results have been presented at several international scientific conferences. FOR FURTHER INFORMATION, PLEASE CONTACT: FORWARD-LOOKING INFORMATION
05.01.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Sernova Corp. |
700 Collip Circle, Ste 114 | |
N6G 4X8 London | |
Canada | |
Internet: | https://www.sernova.com/contact/ |
EQS News ID: | 1265221 |
End of News | DGAP News Service |
|
1265221 05.01.2022
Sernova Corp. Stock
The community is currently still undecided about Sernova Corp. with 2 Buy predictions and 0 Sell predictions.
With a target price of 12 € there is potential for a 6581.51% increase which would mean more than doubling the current price of 0.18 € for Sernova Corp..